{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T23:49:58Z","timestamp":1784159398126,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Pericardiocentesis is an important diagnostic and therapeutic tool for cancer-associated pericardial effusion. Limited safety and outcomes data exists regarding the management of malignancy-related pericardial effusion in patients with thrombocytopenia.<\/jats:p><jats:p><jats:bold>Objectives:<\/jats:bold> Our study aimed to analyze prognostic factors and overall survival (OS) after pericardiocentesis in thrombocytopenic cancer patients.<\/jats:p><jats:p><jats:bold>Methods and Results:<\/jats:bold> A retrospective review of 136 thrombocytopenic cancer patients who underwent primary percutaneous pericardiocentesis was performed. Degree of thrombocytopenia was classified by platelet count recorded on day of pericardiocentesis: 75\u2013149 \u00d7 10<jats:sup>3<\/jats:sup> cells\/\u03bcL (41%); 50\u201374 \u00d7 10<jats:sup>3<\/jats:sup> cells\/\u03bcL (10%); 25\u201349 \u00d7 10<jats:sup>3<\/jats:sup> cells\/\u03bcL (24%); &amp;lt;25 \u00d7 10<jats:sup>3<\/jats:sup> cells\/\u03bcL (25%). Median OS was 2.6 months and median follow-up was 37.4 months. Kaplan-Meier survival analysis showed significant OS differences among thrombocytopenia severity groups (<jats:italic>p<\/jats:italic> = 0.023), and worse OS with platelets &amp;lt;100 vs. \u2265100 \u00d7 10<jats:sup>3<\/jats:sup> cells\/\u03bcL (<jats:italic>p<\/jats:italic> = 0.031). By univariate analysis, thrombocytopenia severity was associated with increased risk of death (HR 0.993; 95% CI 0.989\u20130.997; <jats:italic>p<\/jats:italic> = 0.002). Poor prognostic factors for OS were advanced cancer, malignant effusion, elevated international normalized ratio (INR), quantity of platelet transfusions, and platelet transfusion resistance. However, thrombocytopenia severity became insignificant for OS (<jats:italic>p<\/jats:italic> = 0.802), after adjusting for advanced cancer and INR.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> For patients with malignancy-related large pericardial effusion and thrombocytopenia, pericardiocentesis is a feasible intervention and should be considered due to low complication rates. There is no absolute contraindication to pericardiocentesis in case of hemodynamic instability, even with severe thrombocytopenia.<\/jats:p>","DOI":"10.3389\/fcvm.2021.638943","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:02:13Z","timestamp":1618981333000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic Factors and Overall Survival After Pericardiocentesis in Patients With Cancer and Thrombocytopenia"],"prefix":"10.3389","volume":"8","author":[{"given":"Nathaniel R.","family":"Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence D.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Serauto Canache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Donisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu V.","family":"Balanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhee","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Palaskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lopez-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Cilingiroglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Marmagkiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezar A.","family":"Iliescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.272.1.59","article-title":"Treatment of malignant pericardial effusion","volume":"272","author":"Vaitkus","year":"1994","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11936-018-0654-7","article-title":"Pericardial disease in cancer patients","volume":"20","author":"Ghosh","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/clc.22295","article-title":"Primary malignancies of the heart and pericardium","volume":"37","author":"Burazor","year":"2014","journal-title":"Clin Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.amjcard.2005.01.094","article-title":"Relation of acute pericardial disease to malignancy","volume":"95","author":"Imazio","year":"2005","journal-title":"Am J Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.md.0000199556.69588.8e","article-title":"Large symptomatic pericardial effusion as the presentation of unrecognized cancer: a study in 173 consecutive patients undergoing pericardiocentesis","volume":"85","author":"Ben-Horin","year":"2006","journal-title":"Medicine."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1378\/chest.116.6.1564","article-title":"Bloody pericardial effusion in patients with cardiac tamponade: is the cause cancerous, tuberculous, or iatrogenic in the 1990s?","volume":"116","author":"Atar","year":"1999","journal-title":"Chest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.5603\/KP.2015.0228","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(02)00789-1","article-title":"Platelets and cancer","volume":"3","author":"Nash","year":"2002","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1634\/theoncologist.9-5-561","article-title":"Phan. management of bleeding in patients with advanced cancer","volume":"9","author":"Pereira","year":"2004","journal-title":"Oncologist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2016.05.068","article-title":"Echocardiography and fluoroscopy-guided pericardiocentesis for cancer patients with cardiac tamponade and thrombocytopenia","volume":"68","author":"Iliescu","year":"2016","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2015.06.1332","article-title":"Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion","volume":"66","author":"El Haddad","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B13","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.compbiomed.2012.04.003","article-title":"Pericardial effusion and pericardiocentesis: role of echocardiography","volume":"42","author":"Jung","year":"2012","journal-title":"Korean Circ J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijsu.2015.09.036","article-title":"Thromboelastography and rotational thromboelastometry use in trauma","volume":"33","author":"Abdelfattah","year":"2016","journal-title":"Int J Surg."},{"key":"B16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0022-2143(97)90040-8","article-title":"Monitoring platelet glycoprotein IIb\/IIIa-fibrin interaction with tissue factor-activated thromboelastography","volume":"130","author":"Khurana","year":"1997","journal-title":"J Lab Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1586\/14779072.3.5.941","article-title":"Targeting shear stress-induced platelet activation: is lesion-specific antiplatelet therapy a realistic clinical goal?","volume":"3","author":"Kroll","year":"2005","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B18","first-page":"259","article-title":"Cardiovascular interventions in thrombocytopenic cancer patients","volume":"38","author":"Iliescu","year":"2011","journal-title":"Tex Heart Inst J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fcvm.2020.00009","article-title":"Identifying hemostatic thresholds in cancer patients undergoing coronary angiography based on platelet count and thromboelastography","volume":"7","author":"Agha","year":"2020","journal-title":"Front Cardiovasc Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2015.07.027","article-title":"Echocardiography-guided pericardiocentesis for effusions in patients with cancer revisited","volume":"66","author":"Tsang","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehv479","article-title":"The 2015 ESC guidelines on the diagnosis and management of pericardial diseases","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.hlc.2014.11.009","article-title":"Pericardiocentesis \u2013 how to do it","volume":"24","author":"Gluer","year":"2015","journal-title":"Heart Lung Circ."},{"key":"B23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4103\/2229-5151.165007","article-title":"Complications of pericardiocentesis: a clinical synopsis","volume":"5","author":"Kumar","year":"2015","journal-title":"Int J Crit Illn Inj Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/09537104.2012.749981","article-title":"Pericardiocentesis in patients with thrombocytopenia and high international normalized ratio: case report and review of the literature","volume":"25","author":"Kepez","year":"2014","journal-title":"Platelets."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.638943\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T05:02:18Z","timestamp":1618981338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.638943\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,21]]},"references-count":24,"alternative-id":["10.3389\/fcvm.2021.638943"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.638943","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,21]]},"article-number":"638943"}}